EUVIMEDEUVIMED entdecken
Crossref

Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy

Li-Hsiang Lin, Yan Han, Rui Zhang, Beibei Guo iD

Biometrical Journal · 2023-10 · 65 (7)

DOI: 10.1002/bimj.202200246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrical Journal, online erschienen am 22.05.2023. Verfasst von Li-Hsiang Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA. Hauptthemen laut MEDLINE: Immunotherapy, Biometry, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NIH HHS, American Cancer Society, Louisiana Board of Regents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent success of sequential administration of immunotherapy following radiotherapy (RT), often referred to as immunoRT, has sparked the urgent need for novel clinical trial designs to accommodate the unique features of immunoRT. For this purpose, we propose a Bayesian phase I/II design for immunotherapy administered after standard‐dose RT to identify the optimal dose that is personalized for each patient according to his/her measurements of PD‐L1 expression at baseline and post‐RT. We model the immune response, toxicity, and efficacy as functions of dose and patient's baseline and post‐RT PD‐L1 expression profile. We quantify the desirability of the dose using a utility function and propose a two‐stage dose‐finding algorithm to find the personalized optimal dose. Simulation studies show that our proposed design has good operating characteristics, with a high probability of identifying the personalized optimal dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyBiometryPrecision MedicineBiomarkers, TumorHumansBayes TheoremNeoplasmsB7-H1 Antigen

Stichwörter der Autor:innen

Bayesian adaptive designPD-L1 expressionbiomarkersdose findingimmunoRTimmunotherapypatient subgroupsradiotherapy

Substanzen

Biomarkers, TumorB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.
  • Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA.
  • Department of Radiation Oncology, Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, USA.

ORCID-Profile: Beibei Guo

Förderung

  • NIH HHS
  • American Cancer Society
  • Louisiana Board of Regents
  • National Institutes of Health

Zitieren

APA

Lin, L. H., Han, Y., Zhang, R., & Guo, B. (2023). Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy. Biometrical Journal, 65(7). https://doi.org/10.1002/bimj.202200246

Vancouver

Lin LH, Han Y, Zhang R, Guo B. Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy. Biometrical Journal. 2023;65(7). doi:10.1002/bimj.202200246

BibTeX
@article{Lin2023,
  author = {Lin, Li-Hsiang and Han, Yan and Zhang, Rui and Guo, Beibei},
  title = {Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy},
  journal = {Biometrical Journal},
  year = {2023},
  volume = {65},
  number = {7},
  doi = {10.1002/bimj.202200246}
}
Kostenlos starten →